Iovance rises as Australia approves melanoma therapy Amtagvi
Source: SeekingAlpha
2026-06-04 12:27:47 ET
More on Iovance Biotherapeutics
- Iovance Therapeutics: Q1 Earnings Miss May Have Created A Buying Opportunity
- Iovance Biotherapeutics, Inc. (IOVA) Q1 2026 Earnings Call Transcript
- Iovance Biotherapeutics: Buy, Because Short-Term Competitor Is Out
- Iovance outlines $350M-$370M 2026 revenue, while guiding Q2 total revenue to $86M-$88M
- Iovance slips after Q1 miss amid in-line 2026 outlook
Read the full article on Seeking Alpha
For further details see:
Iovance rises as Australia approves melanoma therapy Amtagvi
Iovance Biotherapeutics Inc.
NASDAQ: IOVA
IOVA Trading
-4.78% G/L:
$4.28 Last:
10,141,648 Volume:
$4.50 Open:
IOVA Latest News
June 03, 2026 04:05:00 pm
Iovance's Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
June 02, 2026 12:35:00 am
Iovance Stock Has Been Hammered. Is This the Buying Opportunity Aggressive Investors Have Been Waiting For?
IOVA Stock Data
$1,034,101,562
356,080,269
0.23%
94
N/A
Biotechnology & Life Sciences
Healthcare
US
San Carlos
